<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576172</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01149</org_study_id>
    <secondary_id>NCI-2012-01149</secondary_id>
    <secondary_id>NCI-2012-01919</secondary_id>
    <secondary_id>12-0109</secondary_id>
    <secondary_id>CDR0000730114</secondary_id>
    <secondary_id>UCCRC-IL057</secondary_id>
    <secondary_id>9012</secondary_id>
    <secondary_id>9012</secondary_id>
    <secondary_id>N01CM00038</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>P50CA097186</secondary_id>
    <secondary_id>U01CA062491</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>UM1CA186691</secondary_id>
    <secondary_id>UM1CA186705</secondary_id>
    <secondary_id>UM1CA186716</secondary_id>
    <nct_id>NCT01576172</nct_id>
  </id_info>
  <brief_title>Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies abiraterone acetate and prednisone together with&#xD;
      veliparib to see how well it works compared to abiraterone acetate and prednisone alone in&#xD;
      treating patients with castration-resistant prostate cancer that has spread from the primary&#xD;
      site to other places in the body. Androgens can cause the growth of prostate cancer cells.&#xD;
      Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by&#xD;
      the body. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Giving abiraterone acetate together with prednisone and veliparib may work&#xD;
      better than abiraterone acetate and prednisone alone in treating patients with&#xD;
      castration-resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the role of v-ets erythroblastosis virus E26 oncogene (ETS) gene fusion as a&#xD;
      predictive biomarker for response to hormone therapy (abiraterone [abiraterone acetate])&#xD;
      alone or hormone therapy plus poly adenosine diphosphate-ribose polymerase 1 (PARP-1)&#xD;
      targeted therapy (ABT-888 [veliparib]) in patients with metastatic castration resistant&#xD;
      prostate cancer.&#xD;
&#xD;
      II. To evaluate whether the addition of PARP-1 targeted therapy is superior to hormone&#xD;
      therapy alone based on ETS gene fusion status.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Rate of prostate-specific antigen (PSA) declines. II. Objective response rate. III.&#xD;
      Progression-free survival. IV. Evaluate the qualitative and quantitative toxicity of&#xD;
      abiraterone acetate with and without ABT-888.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the concordance in fusion status among prostate cancer samples from the&#xD;
      primary site, biopsied metastasis, and circulating tumor cells (CTCs).&#xD;
&#xD;
      II. To assess if ETS fusion status in the CTCs, at baseline, 12 weeks, and disease&#xD;
      progression (or when off study) is associated with response to therapy.&#xD;
&#xD;
      III. To evaluate if the number of CTCs, as well as the expression levels of androgen&#xD;
      receptor, RAD51 recombinase (RAD51), and gamma-H2A histone family, member X (H2aX) foci in&#xD;
      the CTCs at baseline, at 12 weeks, and at disease progression in all patients is associated&#xD;
      with response to therapy.&#xD;
&#xD;
      IV. To determine the role of phosphatase and tensin homolog (PTEN) loss as a predictive&#xD;
      biomarker of response to abiraterone, alone or in combination with ABT-888.&#xD;
&#xD;
      V. To determine the role of PARP1 activity as a predictive biomarker of response to&#xD;
      abiraterone, alone or in combination with ABT-888.&#xD;
&#xD;
      VI. To perform next-generation sequencing for discovery of novel gene fusions in prostate&#xD;
      cancers negative for ETS fusions.&#xD;
&#xD;
      VII. To perform germline single nucleotide polymorphism (SNP) analysis of genes involved in&#xD;
      hormone synthesis, transport, binding, metabolism, and degradation for discovery of novel&#xD;
      SNPs predictive of response to abiraterone, alone or in combination with ABT-888.&#xD;
&#xD;
      VIII. To determine if ETS fusion ribonucleic acid (RNA) levels in blood are predictive of&#xD;
      response to abiraterone, alone or in combination with ABT-888.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive abiraterone acetate orally (PO) once daily (QD) and prednisone PO&#xD;
      twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone&#xD;
      acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for up to 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2012</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Prostate-specific Antigen (PSA) Response Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>50% or greater decline in PSA from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of PSA Decline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in PSA from baseline to 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates in Patients With Measurable Disease.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Overall response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Time from randomization to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 4 or 5 Adverse Events</measure>
    <time_frame>30 days after completion of study treatment</time_frame>
    <description>Grade 4 or greater toxicity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 at least possibly related to treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (abiraterone acetate and prednisone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (abiraterone acetate, prednisone, and veliparib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (abiraterone acetate and prednisone)</arm_group_label>
    <arm_group_label>Arm II (abiraterone acetate, prednisone, and veliparib)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Yonsa</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (abiraterone acetate and prednisone)</arm_group_label>
    <arm_group_label>Arm II (abiraterone acetate, prednisone, and veliparib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (abiraterone acetate and prednisone)</arm_group_label>
    <arm_group_label>Arm II (abiraterone acetate, prednisone, and veliparib)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (abiraterone acetate, prednisone, and veliparib)</arm_group_label>
    <other_name>ABT-888</other_name>
    <other_name>PARP-1 inhibitor ABT-888</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a histologic or cytologic diagnosis of prostate cancer&#xD;
&#xD;
          -  Have progressive metastatic castration-resistant prostate cancer, on&#xD;
             androgen-deprivation therapy, based on at least one of the following criteria:&#xD;
&#xD;
               -  PSA progression defined as 25% increase over baseline value with an increase in&#xD;
                  the absolute value of at least 2 ng/mL that is confirmed by another PSA level&#xD;
                  with a minimum of a 1-week interval with a minimum PSA of 2 ng/mL&#xD;
&#xD;
               -  Progression of bidimensionally measurable soft tissue (nodal metastasis) assessed&#xD;
                  within one month prior to registration by a computed tomography (CT) scan or&#xD;
                  magnetic resonance imaging (MRI) of the abdomen and pelvis&#xD;
&#xD;
               -  Progression of bone disease (evaluable disease) (new bone lesion[s]) by bone scan&#xD;
&#xD;
          -  Agree to undergo a biopsy of at least 1 metastatic site for gene-fusion status&#xD;
             analysis; adequate archival metastatic tissue can be used if available in lieu of a&#xD;
             biopsy; patients will only be eligible for protocol therapy if the biopsy has tumor&#xD;
             and the tissue is evaluable for ETS fusion status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Have testosterone &lt; 50 ng/dL; patients must continue primary androgen-deprivation with&#xD;
             a luteinizing hormone-releasing hormone (LHRH) analogue if they have not undergone&#xD;
             orchiectomy&#xD;
&#xD;
          -  Patients must discontinue antiandrogen therapy for at least 4 weeks (e.g. flutamide,&#xD;
             bicalutamide, nilutamide) prior to registration with no evidence of a falling PSA&#xD;
             after washout; patients on steroids are eligible as long as they will be switched to&#xD;
             prednisone&#xD;
&#xD;
          -  Have no prior exposure to cytochrome 450 family 17(CYP-17) (other than ketoconazole)&#xD;
             or PARP inhibitors for prostate cancer; patients with prior exposure to ketoconazole&#xD;
             are eligible&#xD;
&#xD;
          -  Patients with up to 2 prior chemotherapy regimens are eligible&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: White blood cells (WBC) &gt;= 3,000/ul&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: Absolute neutrophil count (ANC) &gt;=&#xD;
             1,500/ul&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: Platelet count &gt;= 100,000/ul&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: Serum creatinine =&lt; 1.5 x the&#xD;
             institutional upper limits of normal or corrected creatinine clearance of &gt;= 50&#xD;
             mg/ml/hr/1.73 m^2 body surface area (BSA)&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: Potassium &gt;= 3.5 mmol/L&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: Bilirubin within the institutional&#xD;
             limits of normal&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: Serum glutamic oxaloacetic transaminase&#xD;
             (SGOT) (aspartate aminotransferase [AST]) =&lt; 2 times upper limit of normal&#xD;
&#xD;
          -  Obtained within 14 days prior to registration: Serum glutamate pyruvate transaminase&#xD;
             (SGPT) (alanine aminotransferase [ALT]) =&lt; 2 times upper limit of normal&#xD;
&#xD;
          -  Measured within 28 days prior to administration of ABT-888: &gt;= 10.0 g/dL hemoglobin&#xD;
             (Hb) with no blood transfusion in the past 28 days&#xD;
&#xD;
          -  Men must agree to use effective contraception during treatment and for at least 1 week&#xD;
             after the last administration of therapy&#xD;
&#xD;
          -  Patients must be able to take oral medication without crushing, dissolving, or chewing&#xD;
             tablets&#xD;
&#xD;
          -  Patients may have received prior radiation therapy or surgery; however, at least 21&#xD;
             days must have elapsed since completion of radiation therapy or surgery and patient&#xD;
             must have recovered from all side effects at the time of registration&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed-consent document&#xD;
             that is approved by the local institutional review board&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents; any prior&#xD;
             investigational products must be stopped at least 14 days (2-week washout) prior to&#xD;
             registration&#xD;
&#xD;
          -  Patients who have had chemotherapy, radiotherapy or oral antifungal agents&#xD;
             (ketoconazole, itraconazole, fluconazole) within 3 weeks prior to entering the study&#xD;
             or those who have not recovered (e.g. back to baseline or grade 1) from adverse events&#xD;
             due to agents administered more than 3 weeks earlier&#xD;
&#xD;
               -  There is a potential drug interaction when abiraterone is concomitantly used with&#xD;
                  a cytochrome P450 family 2, subfamily D, polypeptide 6 (CYP2D6) substrate narrow&#xD;
                  therapeutic index (e.g., thioridazine, dextromethorphan), or strong cytochrome&#xD;
                  P450 family 3, subfamily A, polypeptide 4 [CYP3A4] inhibitors (e.g., atazanavir,&#xD;
                  erythromycin, indinavir, itraconazole, Ketoconazole, nefazodone, nelfinavir,&#xD;
                  ritonavir, saquinavir, telithromycin, and voriconazole) or strong inducers (e.g.,&#xD;
                  carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine);&#xD;
                  caution should be used when patients are on one of these drugs&#xD;
&#xD;
          -  Patients with history of active seizures are not eligible&#xD;
&#xD;
          -  Patients with a history of pituitary or adrenal dysfunction, active or symptomatic&#xD;
             viral hepatitis, or chronic liver disease are not eligible&#xD;
&#xD;
          -  Patients with known brain metastases should be excluded from this clinical trial&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to ABT-888 or abiraterone&#xD;
&#xD;
          -  Patients may continue on a daily multi-vitamin, calcium and vitamin D, but all other&#xD;
             herbal, alternative and food supplements (i.e. PC-Spes, saw palmetto, St John's wort,&#xD;
             etc.) must be discontinued before registration; patients must not be planning to&#xD;
             receive any concurrent cytotoxic chemotherapy, surgery, or radiation therapy during&#xD;
             protocol treatment; hormonal-acting agents (including diethylstilbestrol/DES,&#xD;
             aldosterone, and spironolactone) are forbidden during the trial and must be stopped&#xD;
             prior to registration; no washout period will be required for any of these agents;&#xD;
             patients on megestrol acetate for hot flashes are allowed to continue therapy&#xD;
&#xD;
          -  Patients on stable doses of bisphosphonates or denosumab which have been started prior&#xD;
             to registration may continue on this medication, patients who are not on&#xD;
             bisphosphonates or denosumab are eligible as long as they initiate therapy prior to&#xD;
             registration&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure (New York Heart Association class III&#xD;
             and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements or&#xD;
             concurrent medications that alter cardiac conduction&#xD;
&#xD;
          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancers are not eligible; patients are not considered to have a &quot;currently active&quot;&#xD;
             malignancy if they have completed all therapy and are now considered without evidence&#xD;
             of disease for 1 year&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
&#xD;
          -  Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic&#xD;
             syndrome (MDS) or with features suggestive of AML/MDS. Prior allogeneic bone marrow&#xD;
             transplant or double umbilical cord blood transplantation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maha H Hussain</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem-Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Women's Health Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>October 21, 2020</results_first_submitted>
  <results_first_submitted_qc>October 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01576172/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Abiraterone Acetate and Prednisone)</title>
          <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Prednisone: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
          <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance issue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Abiraterone Acetate and Prednisone)</title>
          <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
          <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="50" upper_limit="90"/>
                    <measurement group_id="B2" value="68" lower_limit="47" upper_limit="85"/>
                    <measurement group_id="B3" value="68" lower_limit="47" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Prostate-specific Antigen (PSA) Response Rate</title>
        <description>50% or greater decline in PSA from baseline.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>2 patients non-evaluable in Arm I and 3 patients non-evaluable in Arm II due to receiving &lt;2 treatment cycles</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Abiraterone Acetate and Prednisone)</title>
            <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
            <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Prostate-specific Antigen (PSA) Response Rate</title>
          <description>50% or greater decline in PSA from baseline.</description>
          <population>2 patients non-evaluable in Arm I and 3 patients non-evaluable in Arm II due to receiving &lt;2 treatment cycles</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of PSA Decline</title>
        <description>Change in PSA from baseline to 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>3 patients in Arm 1 and 13 patients in Arm 2 had missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Abiraterone Acetate and Prednisone)</title>
            <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Prednisone: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
            <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of PSA Decline</title>
          <description>Change in PSA from baseline to 12 weeks</description>
          <population>3 patients in Arm 1 and 13 patients in Arm 2 had missing data.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.1" spread="15.7"/>
                    <measurement group_id="O2" value="-52.9" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t=-0.39 on 112.7 degrees of freedom (Satterthwaite)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rates in Patients With Measurable Disease.</title>
        <description>Overall response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Subset of patients with measurable disease.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Abiraterone Acetate and Prednisone)</title>
            <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
            <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rates in Patients With Measurable Disease.</title>
          <description>Overall response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>Subset of patients with measurable disease.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Time from randomization to disease progression or death.</description>
        <time_frame>Up to 42 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Abiraterone Acetate and Prednisone)</title>
            <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
            <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Time from randomization to disease progression or death.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.2" upper_limit="13.8"/>
                    <measurement group_id="O2" value="11.0" lower_limit="8.1" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 4 or 5 Adverse Events</title>
        <description>Grade 4 or greater toxicity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 at least possibly related to treatment.</description>
        <time_frame>30 days after completion of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Abiraterone Acetate and Prednisone)</title>
            <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
            <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 4 or 5 Adverse Events</title>
          <description>Grade 4 or greater toxicity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 at least possibly related to treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after completion of study treatment (up to 42 months).</time_frame>
      <desc>Toxicity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 without regard to attribution.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Abiraterone Acetate and Prednisone)</title>
          <description>Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Prednisone: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Abiraterone Acetate, Prednisone, and Veliparib)</title>
          <description>Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Prednisone: Given PO&#xD;
Veliparib: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urostomy obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore Karrison, PhD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>(773) 702-9326</phone>
      <email>tkarrison@health.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

